Drug Type ASO |
Synonyms aldesleukin + TASO-001, aldesleukin + trabedersen, recombinant IL-2 + TGF-beta 2 targeting anti-sense oligonucleotide + [2] |
Target |
Action inhibitors |
Mechanism TGF-β2 inhibitors(Transforming growth factor beta 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 1 | South Korea | 11 May 2023 | |
Renal Cell Carcinoma | Phase 1 | South Korea | 11 May 2023 | |
Metastatic Solid Tumor | Phase 1 | United States | 09 Mar 2021 | |
Solid tumor | Phase 1 | United States | 09 Mar 2021 |
Phase 1/2 | 33 | vyqbspmgol(pwdfqcviqp) = korvkxcmrf rbihtktzkw (fweibihucb ) | - | 20 May 2011 | |||
Phase 1/2 | 33 | ydxwsumnmt(khbgxabrij) = The only expected adverse reaction identified was nonserious, transient thrombocytopenia ifapboeptm (hgrxhgasfn ) View more | - | 20 May 2010 | |||
Phase 1/2 | 33 | klktopwbic(ebobbcmswd) = zklpnjwtop fonqunjwwc (hbyxzpreif ) | - | 20 May 2009 |